首页 >
法规速递
-
Document: Reflection paper on investigation and assessment of cardiovascular safety of anticancer medicinal products-2026/1/23
2026-01-26查看详情 > -
关于公开征求《罕见疾病创新药物研发鼓励试点计划（“关爱计划-延伸”）》相关工作文件意见的通知-2026/2/28
2026-02-28查看详情 > -
Page: Submitting results of paediatric studies-2026/3/27
2026-03-30查看详情 > -
Document: Olazax : EPAR - Procedural steps taken and scientific information after authorisation (archive)-2026/5/11
2026-05-12查看详情 > -
关于公开征求《斑秃治疗药物临床试验技术指导原则》（征求意见稿）意见的通知-2026/6/24
2026-06-25查看详情 > -
组织患者参与药物研发的一般考虑指导原则（试行）-2022/11/25
2022-11-25查看详情 > -
国家药监局药审中心关于发布《糖尿病视网膜病变相关中药新药临床研发技术指导原则（试行）》的通告（2023年第55号）-2023/11/14
2023-11-15查看详情 > -
Document: Work plan for the Committee for Veterinary Medicinal Products (CVMP) Pharmacovigilance Working Party (PhVWP-V) 2025-2025/1/16
2025-01-17查看详情 > -
Document: Minutes of the CVMP meeting 14-15 January 2025-2025/2/20
2025-02-21查看详情 > -
Document: Day 80 assessment report - Clinical template with guidance - Rev. 03.25 - Revamp-2025/3/28
2025-04-01查看详情 >
